| Detailed information |
|---|
| CancerLivER ID | 2545 |
| Biomarker | CDC42EP 4, IVNS1AB P, QTRT1, A2BP1, EDF1, ANXA2P3, ZNF706, STAT6, CDKN1C, DUSP6, PLOD1, ATP2A3, FAM65A, SIPA1, NCK2 |
| Biomarker Name/Symbol (given in Publication) | CDC42EP 4, IVNS1AB P, QTRT1, A2BP1, EDF1, ANXA2P3, ZNF706, STAT6, CDKN1C, DUSP6, PLOD1, ATP2A3, FAM65A, SIPA1, NCK2 |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential marker for early HCC diagnosis in high risk cirrhotic HCV patients; but not validated on independent dataset |
| Experimental Condition | HCV-Cirrhosis v/s HCV-Cirrhosis with HCC |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Downregulated in HCV-Cirrhosis with HCC than HCV-cirrhosis only (with fold change more than 1.3) |
| Level of significance | p < 0.05 |
| Source | Tissue |
| PMID | 19098997 |
| Type of Biomarker | Prognostic |
| Pathway | Apoptosis, angiogenesis, mmune response , response to stress |
| Cohort | 108 liver tissue samples obtained from 88 distinct patients:Normal livers (N=19), HCV cirrhosis (N=41), early HCCs (T1N0M0 and T2N0M0, N=26), advanced HCCs (T3N0M0 and T4N0M0, N=13), and very advanced HCCs (T4N0M1, N=7). |
| Sensitivity | 100% |
| Specificity | 87.50% |
| Accuracy | 96.40% |
| AUC | NA |
| Disease | HCV-Cirrhosis v/s HCV-Cirrhosis with HCC |
| Year of Publication | 2009 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |